Barclays PLC Alvotech Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Alvotech stock. As of the latest transaction made, Barclays PLC holds 21,024 shares of ALVO stock, worth $179,124. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,024
Previous 21,024
-0.0%
Holding current value
$179,124
Previous $192,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ALVO
# of Institutions
54Shares Held
16.4MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.23MShares$36.1 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$23 Million14.1% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca1.56MShares$13.3 Million0.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.39MShares$11.8 Million0.0% of portfolio
-
Littlejohn & CO LLC1.32MShares$11.2 Million11.48% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $2.12B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...